XBIT 250117 17.50P (XBIT250117P17500) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayNot Open Dec 26 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Dec 23 08:09

$XBiotech (XBIT.US)$ XBiotech Halts Rheumatology Program After Phase II Rheumatoid Arthritis Study Fails To Meet Primary Endpoint Amid Data Irregularities; Future Studies On Hold Pending Further Analysis Of Findings

Stock Region

Jun 21 10:19

Biotechnology Company Announces Promising Data From Advanced Pancreatic Cancer Study

XBiotech's Phase 1/2 Study on Advanced Pancreatic Cancer: A Detailed Review.
XBiotech (NASDAQ: XBIT) recently announced promising data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Named 1-BETTER, this study focused on evaluating Natrunix, an anti-interleukin-1alpha antibody, in combination with a well-established chemotherapy regimen comp...

Jaguar8

Jun 18 12:04

NEWS

$XBiotech (XBIT.US)$
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech (NASDAQ: XBIT) announced promising results from its Phase 1/2 trial for advanced pancreatic cancer treatment using Natrunix in combination with a standard chemotherapy regimen. The study, titled 1-BETTER, enrolled 65 subjects who received either the Natrunix combination or a placebo. Key findings include a 28% reduction in signif...

Moomoo AI

Nov 14, 2023 08:07

XBiotech believes that Natrunix will be a breakthrough therapy for rheumatological diseases. The company is eagerly anticipating the results of the Phase II study. Dr. Kivitz expressed excitement in investigating a novel approach towards treating Rheumatoid Arthritis through Natrunix.

Press Release: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis

54088 FROM RWS

Jul 29, 2021 19:25

$XBiotech (XBIT.US)$
Where can check this information?
If I have 10 share....
Where is the money? 🧐